Dawnrays Pharmaceutical Holdings Ltd ($2348) - buy or sell? Stock discussion, ideas, forum

Dawnrays Pharmaceutical Holdings Ltd

Dawnrays Pharmaceutical (Holdings) Limited, through its subsidiaries, develops, manufactures, and sells non-patented chemical medicines including cephalosporins in sterile bulk medicine and powder for injection forms, their intermediate pharmaceuticals and system specific medicines.

Industry: Pharmaceuticals

Ticker	Exchange	ISIN	Name
$2348	HKEx Main Board	KYG2687M1006	Code: 2348

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 2348 stock

Share your investment idea or question on Dawnrays Pharmaceutical Holdings Ltd stock:

Latest twits on Dawnrays Pharmaceutical Holdings Ltd (2348)

No twits yet. Be the first to post!

Have a question about 2348? Ask and other investors will be eager to help you.

Have an idea about 2348? Share it with other investors.

Dawnrays Pharmaceutical Holdings Ltd news

24/03/2017 Dawnrays Pharmaceutical Holdings Ltd EBITDA Margin dropped on 41.5 pp from 41.5% to in 2016

17/03/2016 Dawnrays Pharmaceutical Holdings Ltd reports 47.3% Net Income growth and 3.1 pp EBITDA Margin growth from 38.5% to 41.5%

Dawnrays Pharmaceutical Holdings Ltd stock price chart

Dawnrays Pharmaceutical Holdings Ltd financials

mln. CNY	FY2010	FY2011	FY2012

Revenue	1,287	1,081	856.5
EBITDA	233.9	203.7	173.7
Net income	166.8	146.3	114.5
CAPEX	83.660	148.1	107.6
Debt	51.156	110.5	201.8
Cash	211.0	97.805	155.7